Select a medication above to begin.
Syfovre
pegcetacoplan intravitreal
Adult Dosing .
Dosage forms: INJ
geographic atrophy, age-related macular degeneration-associated
- [15 mg intravitreally q25-60 days]
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- ocular infection
- periocular infection
- intraocular inflammation, active
- caution: patients of childbearing potential
Drug Interactions .
Overview
pegcetacoplan intravitreal
complement inhibitor
-
None
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
Serious Reactions
- ocular infection
- periocular infection
- intraocular inflammation
- endophthalmitis
- retinal detachment
- age-related macular degeneration, neovascular
- optic ischemic neuropathy
- retinal vasculitis
- retinal vascular occlusion
- hypersensitivity rxn
- anaphylaxis
Common Reactions
- ocular discomfort
- age-related macular degeneration, neovascular
- vitreous floaters
- conjunctival hemorrhage
- vitreous detachment
- retinal hemorrhage
- punctate keratitis
- posterior capsule opacification
- intraocular inflammation
- IOP incr.
Safety/Monitoring .
Monitoring Parameters
IOP (tonometry) prior to and immediately post-injection
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available, though risk of fetal harm not expected based on minimal systemic absorption; possible risk of embryo-fetal toxicity and death based on animal data w/ SC route at 1040x maximum recommended human ophthalmic dose
Individuals of Reproductive Potential
avoid pregnancy by using effective contraception during tx and x40 days after D/C in patients of childbearing potential
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available, though risk of infant harm and adverse effects on milk production not expected based on minimal systemic absorption in breastfeeding patients
Pharmacology .
Metabolism: catabolism; CYP450: unknown; Info: minimal systemic absorption
Excretion: unknown; Half-life: 4.5 days
Subclass: Complement Inhibitors, Ophthalmic ; Macular Diseases
Mechanism of Action
binds complement protein C3 and C3b, inhibiting C3 cleavage and its downstream complement activation cascade
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.